Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3 for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-664

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-664 Category Tag

Product Details

Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Ensomafusp Biosimilar, Fusion Protein targeting CD19: Recombinant therapeutic protein targeting B4/CVID3

INN Name

Ensomafusp

Target

CD19

Format

Fusion Protein

Derivation

Humanized

Species Reactivity

Human

CH1 Isotype

G1

VD LC

Kappa

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Active

100% SI Structure

None

99% SI Structure

None

95-98% SI Structure

None

Year Proposed

2021

Companies

Roche

Conditions Approved

NA

Conditions Active

B cell Lymphoma

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

CD19

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide